Price (delayed)
$8.74
Market cap
$433.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.02
Enterprise value
$458.44M
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
There are no recent dividends present for RGNX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.